Tuttlingen – In a joint position paper, 22 manufacturers and users of fluoropolymers as well as associations such as MedicalMountains GmbH call for a differentiated view of the risk profiles and intended uses of each group in the event of possible restrictions – also with a view to medical technology.
The letter is addressed to authorities in Denmark, Germany, the Netherlands, Norway and Sweden as well as to representatives of the EU Commission. "The use of fluoropolymers brings significant advantages along the entire value chain," state the signatories. The unmatched chemical and temperature resistance and unique electrical properties resulted in a unique, durable and sustainable performance. Due to their longevity, fluoropolymers are ideal materials for the development of innovative technologies. Alternative materials could not meet these requirements. A general restriction of fluoropolymers would therefore have far-reaching consequences - in addition to other points also for patient safety.
The signatories therefore urge that when restricting PFAS under the REACH regulation, the various PFAS groups should be distinguished according to their respective risk profiles and properties, and that the safe use of fluoropolymers and their importance for applications be recognized - and thus exemptions from regulatory measures enable.
The position paper is available at this link.
Note: The EU Focus Group invites you to the free online event “The EU Green Deal in need of Fluoropolymers” on Monday 23 January. Start is at 2:00 p.m. More information and registration at this link.
